NCT00870155View on ClinicalTrials.gov

A Study for Patients With Multiple Sclerosis

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Secondary Progressive Multiple Sclerosis
Interventions
DRUG

dirucotide

500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination

Trial Locations (10)

1015

Vecmilgravis Hospital, Riga

2100

Copenhagen University Hospital, Copenhagen

10617

West Tallinn Central Hospital, Tallinn

14186

Karolinska Universitetssjukhus, Stockholm

20101

Terveystalo Turku Kuvantaminen, Turku

40225

Heinrich Heine Universitaets, Düsseldorf

M5B 1W8

St. Michaels Hospital, Toronto

6131BK

Maaslandziekenhuis, Sittard

08907

Hospital Duran I Reynals, Barcelona

L97LJ

Walton Hospital, Liverpool

Sponsors

Collaborators (1)

BioMS Technology Corp.
All Listed Sponsors
collaborator

BioMS Technology Corp.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY